Literature DB >> 8359187

Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites.

A J McLachlan1, D J Cutler, S E Tett.   

Abstract

The in vitro binding of the enantiomers of hydroxychloroquine and its three major metabolites in pooled plasma obtained from four healthy volunteers and the binding of the enantiomers of hydroxychloroquine to purified plasma proteins has been investigated. The plasma protein binding of hydroxychloroquine was found to be stereoselective. The (S)-enantiomer of hydroxychloroquine was 64% bound in plasma, while (R)-hydroxychloroquine was 37% bound. Fifty% of (S)-hydroxychloroquine was bound to a 40 g.l-1 solution of human serum albumin, while only 29% of the (R)-enantiomer was bound. The enantioselectivity of hydroxychloroquine binding was reversed in a 0.7 g.l-1 solution of alpha 1-acid glycoprotein with (R)-hydroxychloroquine being bound to a greater extent than its optical antipode (41% versus 29%). The enantiomers of the metabolites of hydroxychloroquine were bound to a similar extent to plasma and purified plasma proteins. Binding of hydroxychloroquine to plasma and purified proteins was found to be linear over the racemic concentration range of 50 to 1000 ng.ml-1 and hydroxychloroquine metabolite binding to plasma was linear over the range 25 to 500 ng.ml-1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8359187     DOI: 10.1007/BF00315548

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  High-performance liquid chromatographic separation of the enantiomers of hydroxychloroquine and its major metabolites in biological fluids using an alpha 1-acid glycoprotein stationary phase.

Authors:  A J McLachlan; S E Tett; D J Cutler
Journal:  J Chromatogr       Date:  1991-09-18

Review 2.  Stereoselectivity in pharmacokinetics: a general theory.

Authors:  R H Levy; A V Boddy
Journal:  Pharm Res       Date:  1991-05       Impact factor: 4.200

Review 3.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part I).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.

Authors:  K M Piafsky; O Borgå
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

5.  The plasma protein binding of basic drugs.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

Review 6.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

7.  Protein binding of chloroquine enantiomers and desethylchloroquine.

Authors:  D Ofori-Adjei; O Ericsson; B Lindström; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

9.  A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers.

Authors:  S E Tett; D J Cutler; R O Day; K F Brown
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

10.  Characterization of chloroquine plasma protein binding in man.

Authors:  O Walker; D J Birkett; G Alván; L L Gustafsson; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

View more
  16 in total

Review 1.  Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors:  N Fathy; D E Furst
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.

Authors:  Anil R Maharaj; Huali Wu; Christoph P Hornik; Stephen J Balevic; Chi D Hornik; P Brian Smith; Daniel Gonzalez; Kanecia O Zimmerman; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  JAMA Pediatr       Date:  2020-10-05       Impact factor: 16.193

Review 3.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 4.  Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats.

Authors:  J Emami; F M Pasutto; F Jamali
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

Review 6.  Disease-modifying antirheumatic drugs. Potential effects in older patients.

Authors:  G Gardner; D E Furst
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

Review 7.  Clinical pharmacokinetics of slow-acting antirheumatic drugs.

Authors:  S E Tett
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

8.  Clearing the complexity: immune complexes and their treatment in lupus nephritis.

Authors:  Catherine Toong; Stephen Adelstein; Tri Giang Phan
Journal:  Int J Nephrol Renovasc Dis       Date:  2011-01-11

9.  Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness.

Authors:  Mahmoud Al-Kofahi; Pamala Jacobson; David R Boulware; Arthur Matas; Raja Kandaswamy; Mutaz M Jaber; Radha Rajasingham; Jo-Anne H Young; Melanie R Nicol
Journal:  Clin Pharmacol Ther       Date:  2020-06-01       Impact factor: 6.903

Review 10.  Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.

Authors:  Efstathios Kastritis; Ashutosh Wechalekar; Stefan Schönland; Vaishali Sanchorawala; Giampaolo Merlini; Giovanni Palladini; Monique Minnema; Murielle Roussel; Arnaud Jaccard; Ute Hegenbart; Shaji Kumar; Maria T Cibeira; Joan Blade; Meletios A Dimopoulos
Journal:  Br J Haematol       Date:  2020-07-04       Impact factor: 8.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.